product datasheets, catalogs, app notes

51. MilliporeSigma Gene Therapy Capabilities 9/22/2021

    You’ve created a gene therapy with the possibility to help patients. But the development and manufacturing of your gene therapy, how it’s developed, produced and approved, are still being outlined. No process template exists. Our products and services for AAV, Lentivirus and other viral vectors provide solutions to your most challenging pain points around process development, speed, manufacturing and regulatory guidelines.

52. Stemline® Platform Media – For Optimized Stem Cell Expansion 9/7/2021

    To obtain enough cells for stem cell-based therapies, ex vivo expansion is utilized to ensure successful engraftment and economize the manufacture of both allogeneic and autologous therapies. We have developed the Stemline® Platform of cGMP-manufactured media, optimized for the expansion of various adult stem cell types in automated manufacturing environments.

53. CellPrime® rAlbumin 8/25/2021

    CellPrime® rAlbumin is a non-animal origin (NAO) recombinant media supplement that is GMP manufactured according to EXCiPACT™. It combines excellent quality with superior performance and  lot-to-lot consistency.

54. Optimization Strategy And Process Economics Of DNA Digestion In Viral Vector Production For Gene Therapy 12/16/2020

    Benzonase® endonuclease is a high-quality product delivering immense value to viral vector processes. The enzyme activity is strongly influenced by the matrix, and optimization of its use should be a mandatory step in process development. In this application note, we highlight an optimization strategy and process economics of DNA digestion in viral vector purification.

55. Tangential Flow Filtration (UF/DF) Of Plasmid DNA 12/16/2020

    Learn how optimization of hydraulic parameters can help you achieve the desired plasmid purity, formulation, and concentration specifications.

56. Sterilizing Grade Filtration Unit Operations For Plasmid DNA Processes 11/19/2020

    The large size of pDNA can present a challenge for sterile filtration unit operations within your gene therapy manufacturing since the product can be retained by the filters, leading to both yield loss and low filtration capacity. Optimization of a sterilized grade filtration unit can help increase yield and filtration capacity. Read on to learn more!

57. Chromatographic Purification Of Plasmid DNA 11/19/2020

    Widespread application of pDNA in gene therapy is driving increased demand and as a response, plasmid manufacturing must become more efficient with improved productivity. Intensification of chromatographic steps can help address this demand and has led to an exploration of the use of convective media (monoliths, membranes, fibre based technologies).

58. How Pattern Search Finds Anomaly Patterns In Historical Machine Data 10/21/2020

    Owing to the sheer volume of data streaming from sensor profiles, anomalies observed during process monitoring in historical data are extremely difficult to search due to a lack of time series search tools. 

59. Next-Gen Bioprocess Monitoring: Smart Data Management And Analysis 10/14/2020

    A new platform that includes digital technologies/data management, process analytical technologies and intensified processing will drive next generation bioprocessing.

60. Cell And Gene Therapy Definitions For Raw Materials, Starting Materials, Drug Substance And Drug Product 8/25/2020

    The complexity of processes to manufacture cell and gene therapy medicinal products can cause confusion around definitions of raw materials, starting materials, process intermediates, drug substance and drug products. This document will discuss the definitions of the above process components.